Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events:...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Percutaneous coronary intervention (PCI) requires effective platelet inhibition to prevent thrombotic events.
• While PCI reduces thrombotic risks, it doesn't consistently prevent restenosis.
• The benefit of enhanced antiplatelet therapy with ticlopidine pretreatment before PCI remains underexplored.

Purpose of the Study:

• To investigate the role of ticlopidine pretreatment in reducing early and late complications following coronary stenting.
• To evaluate the efficacy of enhanced antiplatelet protection with ticlopidine in the context of PCI.

Main Methods:

• The study analyzed data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial.
• Approximately 1600 patients undergoing stenting were randomized to receive placebo or abciximab, alongside aspirin and heparin.
• Ticlopidine was administered post-procedure, with 58% receiving it pre-stenting at physician discretion.

Main Results:

• Among placebo recipients, ticlopidine pretreatment significantly decreased the composite endpoint of death, myocardial infarction, or target vessel revascularization (TVR) at 1 year (HR, 0.73; P=.036).
• Ticlopidine pretreatment did not significantly impact death or myocardial infarction rates in patients receiving abciximab.
• Cox regression identified ticlopidine pretreatment as an independent predictor for reduced TVR at 1 year in both placebo and abciximab groups (HR, 0.62; P=.010).

Conclusions:

• Pretreatment with ticlopidine before PCI was associated with a significant reduction in the 12-month composite endpoint for patients not receiving abciximab.
• Ticlopidine pretreatment independently predicted a lower need for TVR at 1 year across all stented patients.
• Enhanced antiplatelet protection with ticlopidine before stenting may improve outcomes by reducing TVR.